EPIDEMIOLOGY AND HEALTH DATA INSIGHTS
Case Report
Mar 27, 2026 2 1

Probable Ticagrelor-Associated Acute Asthma Exacerbation Following Percutaneous Coronary Intervention: A Case Report

Fangying Cao 1,
Hongliang Xiong 1,
Xiandu Luo 1,
Jiabing Huang 1 * ,
Lingjuan Zhou 2 *
1 Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China2 Department of Cardiology, The Fifth People's Hospitol of Jinan, Jinan, China* Corresponding Author
Epidemiology and Health Data Insights, 2(2), 2026, ehdi033, https://doi.org/10.63946/ehdi/18255
Publication date: Mar 27, 2026
Full Text (PDF)

ABSTRACT

A 57-year-old female with well-controlled bronchial asthma underwent percutaneous coronary intervention (PCI). Three hours after administration of a ticagrelor 180 mg loading dose, she developed severe bronchospasm, with oxygen saturation decreasing from 100% to below 90%. The patient received nasal mask oxygen, repeated nebulization with budesonide suspension, salbutamol, and ipratropium bromide, along with concurrent intravenous methylprednisolone. She was discharged from the ICU within 48 hours; clopidogrel 75 mg was substituted, and there was no recurrence. Severe acute asthma attacks, though rare, possibly induced by ticagrelor, require prompt recognition and aggressive management to prevent respiratory failure during PCI.

KEYWORDS

Ticagrelor Asthma Antiplatelet Therapy Percutaneous Coronary Intervention

CITATION (Vancouver)

Cao F, Xiong H, Luo X, Huang J, Zhou L. Probable Ticagrelor-Associated Acute Asthma Exacerbation Following Percutaneous Coronary Intervention: A Case Report. Epidemiology and Health Data Insights. 2026;2(2):ehdi033. https://doi.org/10.63946/ehdi/18255
APA
Cao, F., Xiong, H., Luo, X., Huang, J., & Zhou, L. (2026). Probable Ticagrelor-Associated Acute Asthma Exacerbation Following Percutaneous Coronary Intervention: A Case Report. Epidemiology and Health Data Insights, 2(2), ehdi033. https://doi.org/10.63946/ehdi/18255
Harvard
Cao, F., Xiong, H., Luo, X., Huang, J., and Zhou, L. (2026). Probable Ticagrelor-Associated Acute Asthma Exacerbation Following Percutaneous Coronary Intervention: A Case Report. Epidemiology and Health Data Insights, 2(2), ehdi033. https://doi.org/10.63946/ehdi/18255
AMA
Cao F, Xiong H, Luo X, Huang J, Zhou L. Probable Ticagrelor-Associated Acute Asthma Exacerbation Following Percutaneous Coronary Intervention: A Case Report. Epidemiology and Health Data Insights. 2026;2(2), ehdi033. https://doi.org/10.63946/ehdi/18255
Chicago
Cao, Fangying, Hongliang Xiong, Xiandu Luo, Jiabing Huang, and Lingjuan Zhou. "Probable Ticagrelor-Associated Acute Asthma Exacerbation Following Percutaneous Coronary Intervention: A Case Report". Epidemiology and Health Data Insights 2026 2 no. 2 (2026): ehdi033. https://doi.org/10.63946/ehdi/18255
MLA
Cao, Fangying et al. "Probable Ticagrelor-Associated Acute Asthma Exacerbation Following Percutaneous Coronary Intervention: A Case Report". Epidemiology and Health Data Insights, vol. 2, no. 2, 2026, ehdi033. https://doi.org/10.63946/ehdi/18255

REFERENCES

  1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57. doi:10.1056/NEJMoa0904327
  2. Bonaca MP, Bhatt DL, Oude OT, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Špinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016;1(4):425–32. doi:10.1001/jamacardio.2016.1017
  3. Alexopoulos D, Xanthopoulou I, Perperis A, Goudevenos J, Hamilos M, Sitafidis G, Kanakakis I, Vavouranakis M, Giannopoulos G, Barampoutis N, Deftereos S, Lekakis J. Dyspnea in patients treated with P2Y(12) receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry. Platelets. 2017;28(7):691–7. doi:10.1080/09537104.2016.1265919
  4. Kim G, Cannon CP. Ticagrelor-Induced Dyspnea: A Controllable Side Effect. JACC Cardiovasc Interv. 2023;16(20):2525–7. doi:10.1016/j.jcin.2023.09.009
  5. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin L. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011;32(23):2945–53. doi:10.1093/eurheartj/ehr231
  6. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503–9. doi:10.1016/j.jacc.2014.03.031
  7. Alsharif KF, Thomas MR, Judge HM, Khan H, Prince LR, Sabroe I, Ridger VC, Storey RF. Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascul Pharmacol. 2015;71:201–7. doi:10.1016/j.vph.2015.02.006
  8. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJJ, Jonasson J, Nylander S, Gan LM. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61(7):723–7. doi:10.1016/j.jacc.2012.11.032
  9. Demir EA, Gonder O. Ticagrelor-related dyspnea beyond adenosine: Insights into retrotrapezoid hyperactivity. Respir Physiol Neurobiol. 2025;331:104349. doi:10.1016/j.resp.2024.104349
  10. Athari SS. Targeting cell signaling in allergic asthma. Signal Transduct Target Ther. 2019;4:45. doi:10.1038/s41392-019-0079-0

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.